Nonvalvular Atrial Fibrillation*
Apixaban Randomized
Controlled Clinical Trial Data
Controlled Clinical Trial Data
Hohnloser SH (Circulation. 2019)
ARISTOTLE Weight Subgroup Analysis (post hoc)
ARISTOTLE Weight Subgroup Analysis (post hoc)
Sandhu RK (Eur Heart J. 2016)
ARISTOTLE BMI Post Hoc Analysis
ARISTOTLE BMI Post Hoc Analysis
Real-world Data
Deitelzweig S (J Clin Med. 2020)
Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study.
Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study.
Deitelzweig S (Am J Cardiol. 2022)
Apixaban vs warfarin in obese patients with NVAF enrolled in Medicare and VA.
Apixaban vs warfarin in obese patients with NVAF enrolled in Medicare and VA.
Briasoulis A (Cardiovasc Drugs Ther. 2021)
Comparative effectiveness and safety of DOACs in obese patients with AF.
Comparative effectiveness and safety of DOACs in obese patients with AF.
O'Kane CP (Pharmacotherapy. 2022)
Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2.
Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2.
Kushnir M (Lancet Haematol. 2019)
Single-center, retrospective analysis of DOACs vs warfarin in morbidly obese patients.
Single-center, retrospective analysis of DOACs vs warfarin in morbidly obese patients.
